Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of MK-5684 versus alternate abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
MOH_2023-12-20_013128Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of opevesostat, abiraterone and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Merck & Co. Primary endpoint: Radiographic progression-free survival. Started Dec 2023; status: recruiting.
02
Drugs
opevesostatabirateroneenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on MOH_2023-12-20_013128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-12-20_013128.